Table 1.
Primersa | Sequence (5′–3′)b | Product size (bp) | Use |
---|---|---|---|
1F | GGTTTAAACTAGCCGCCAGCGGCTTGACC (Dra I) | 1920 | Nsp9 gene amplification |
1R | GGAAGCTTCTCATGATTGGACCTGAGTTT (HindIII) | ||
2F | GGCATATGATGTCGAGTTATTCAAGTGAC (Nde I) | 1845 | DDX5 gene amplification |
2R | GCGGATCCTTATTGAGAATATCCTGTTGG (BamH I) | ||
3F | GGTTTAAACTAGCCGCCAGCGGCTTGACC (Sal I) | pCMV-HA-Nsp9 construction | |
3R | GGAAGCTTCTCATGATTGGACCTGAGTTT (Kpn I) | ||
4F | GGCATATGATGTCGAGTTATTCAAGTGAC (Sal I) | pCMV-Myc-DDX5 construction | |
4R | GCGGATCCTTATTGAGAATATCCTGTTGG (Kpn I) | ||
5F | GCGTTTAAACCTAGCCGCCAGCGGCTTGACC (Pme I) | pWPXL-Nsp9 construction | |
5R | GCACGCGTCTCATGATTGGACCTGAGTTT (Mlu I) | ||
6F | GCGTTTAAACATGTCGAGTTATTCAAGTGAC (Pme I) | pWPXL-DDX5 construction | |
6R | GCACGCGTTTATTGAGAATATCCTGTTGG (Mlu I) | ||
7F | CGGTCGACCCTAGCCGCCAGCGGCTTGACC (Sal I) | pCMV-HA-Nsp9-N construction | |
7R | CGGCGGCCGCTAGGACCGGGGCTTGTAGCTC (Not I) | ||
8F | CCGTCGACGGCAGGTGCCTTGAAGCTGAT (Sal I) | pCMV-HA-Nsp9-C construction | |
8R | CCGCGGCCGCCTCATGATTGGACCTGAGTTT (Not I) | ||
9F | GCAGATCTCCATGTCGAGTTATTCAAGTGAC (Bgl II) | pCMV-Myc-DDX5-N construction | |
9R | GCGCGGCCGCGGTACTGCGGGCAGTTCTTCC (Not I) | ||
10F | GCGAATTCGGAAAACAGGCACAGCATACACT (EcoR I) | pCMV-Myc-DDX5-C construction | |
10R | GCGGTACCTTATTGAGAATATCCTGTTGGC (Kpn I) |
F denotes forward PCR primer; R denotes reverse PCR primer.
Restriction sites are underlined.